Volume 32, Number 1—January 2026
Research Letter
Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025
Shoko Komatsu, Noriko Nakanishi
, Kousaku Matsubara, Yuui Inenaga, Masayuki Hori, Kiyo Shiotani, Rumi Morimoto, Chie Nantani, Yuki Muneta, and Nobuya Kusunoki
, Kousaku Matsubara, Yuui Inenaga, Masayuki Hori, Kiyo Shiotani, Rumi Morimoto, Chie Nantani, Yuki Muneta, and Nobuya Kusunoki
Table
Clinical features and microbiological profiles of 15 MT27-Bordetella pertussis isolates in Kobe, Japan, January 2013–March 2025*
| Strain ID | Collection date | Patients |
Macrolide susceptibility | Genotyping of virulence-related genes |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Age/sex | Vaccination (no. doses) | ptxP | ptxA | fhaB | fim3 | prn | |||
| KBP0005 | 2013 Mar 25 | 1 y/M | DPT (3) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0006 | 2015 Apr 21 | 4 mo/F | NA | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0007 | 2016 Feb 25 | 8 mo/M | Unvaccinated | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0009 | 2019 Sep 24 | 1 mo/F | Unvaccinated | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0010 | 2024 Jun 24 | 1 mo/F | Unvaccinated | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0011 | 2024 Jun 24 | 35 y/M | DPT (4) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0014 | 2025 Jan 25 | 8 y/F | DPT-IPV (4) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0016 | 2025 Feb 3 | 10 y/F | DPT-IPV (4) | Resistant | 3 | 1 | 1 | 1 | 150 |
| KBP0017 | 2025 Feb 12 | 2 mo/M | DPT-IPV (1) | Resistant | 3 | 1 | 1 | 1 | 150 |
| KBP0018 | 2025 Feb 13 | 12 y/M | DPT-IPV (4) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0019 | 2025 Feb 18 | 9 y/F | DPT-IPV (4) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0020 | 2025 Feb 20 | 10 y/F | DPT-IPV (4) | Resistant | 3 | 1 | 1 | 1 | 150 |
| KBP0025 | 2025 Mar 7 | 12 y/F | DPT-IPV (4) | Susceptible | 3 | 1 | 1 | 1 | 2 |
| KBP0026 | 2025 Mar 7 | 12 y/F | NA | Resistant | 3 | 1 | 1 | 1 | 150 |
| KBP0028 | 2025 Mar 12 | 12 y/F | NA | Resistant | 3 | 1 | 1 | 1 | 150 |
*DPT, diphtheria-pertussis-tetanus; IPV, inactivated polio vaccine; MT, multilocus variable-number tandem-repeat analysis type; NA, not available.
Page created: December 30, 2025
Page updated: January 29, 2026
Page reviewed: January 29, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.